Marker Therapeutics, Inc. announced it has been awarded a $9.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). This funding is designated to support the clinical investigation of MT-601 in patients with metastatic pancreatic cancer, specifically for the Phase 1 PANACEA study.
The grant underscores the innovation of Marker's therapy and its potential impact, following a rigorous review process by expert panels. This award, combined with a recent $2 million NIH SBIR grant for MT-601 in pancreatic cancer, totals $11.5 million dedicated to this new indication.
The company plans to initiate the clinical program for MT-601 in pancreatic cancer in 2025, leveraging these non-dilutive funds. This expands the potential application of MT-601 beyond lymphoma and builds on previous academic Phase 1 data that showed favorable safety and durable cancer control in pancreatic cancer patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.